ERBB2 and breast carcinoma: Trastuzumab, a humanized monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), when combined with chemotherapy in neoadjuvant or adjuvant setting, has remarkably improved response rates and survival outcomes of patients with HER2‐positive early or locally advanced breast cancer.1, 2, 3, 4, 5